Polymerase chain reaction-based and Sanger gene sequencing-base assays were undertaken to assess the contribution of genetic polymorphism in GSTM1 and GSTP1 to the susceptibility of bladder cancer (Fig. 1). The gene discussed is GSTM1; the disease is urinary bladder carcinoma.